Christopher C. Goodnow
Directeur/Membre du Conseil chez The Garvan Institute of Medical Research
Profil
Christopher C.
Goodnow was the founder of Phenomix Corp.
which was founded in 2002, where he held the title of Chief Scientific Officer from 2002 to 2010.
Currently, he is the Executive Director at The Garvan Institute of Medical Research since 2015.
Postes actifs de Christopher C. Goodnow
| Sociétés | Poste | Début |
|---|---|---|
The Garvan Institute of Medical Research
 The Garvan Institute of Medical Research Miscellaneous Commercial ServicesCommercial Services The Garvan Institute of Medical Research engages in the provision of biomedical research. It focuses in cancer, genomics and epigenetics, immunity and inflammation, healthy ageing, clinical trials, and research centres. The company was founded in 1963 and is headquartered in Darlinghurst, Australia. | Directeur/Membre du Conseil | 01/01/2015 |
Anciens postes connus de Christopher C. Goodnow
| Sociétés | Poste | Fin |
|---|---|---|
Phenomix Corp.
 Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Fondateur | 28/10/2010 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Health Technology |
The Garvan Institute of Medical Research
The Garvan Institute of Medical Research Miscellaneous Commercial ServicesCommercial Services The Garvan Institute of Medical Research engages in the provision of biomedical research. It focuses in cancer, genomics and epigenetics, immunity and inflammation, healthy ageing, clinical trials, and research centres. The company was founded in 1963 and is headquartered in Darlinghurst, Australia. | Commercial Services |
